$CAPR
CAPRICOR THERAPEUTICS, INC. Stock $capr

$capr Overview Financials Valuation SEC Filings Company Website

2014 Q4 Form 10-Q Financial Statement

#000114420414067974 Filed on November 14, 2014

Income Statement

Concept	2014 Q4	2014 Q3	2013 Q4
Revenue	$1.400M	$1.301M	$500.0K
YoY Change	180.0%	1518.1%	-70.59%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$680.0K	$820.0K	$1.300M
YoY Change	-47.69%	46.43%	4233.33%
% of Gross Profit
Research & Development	$2.580M	$1.967M	$5.070M
YoY Change	-49.11%	94.64%	205.42%
% of Gross Profit
Depreciation & Amortization	$10.00K	$10.00K	$30.00K
YoY Change	-66.67%	-200.0%	50.0%
% of Gross Profit
Operating Expenses	$3.270M	$2.787M	$6.370M
YoY Change	-48.67%	76.98%	279.17%
Operating Profit		-$1.485M
YoY Change		-0.6%
Interest Expense	-$60.00K	$60.09K	-$10.00K
YoY Change	500.0%	157.32%	-133.33%
% of Operating Profit
Other Income/Expense, Net		-$58.88K	$330.0K
YoY Change		15.06%	-176.74%
Pretax Income	-$1.930M	-$1.540M	-$7.460M
YoY Change	-74.13%	-0.65%	1863.16%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$1.930M	-$1.544M	-$7.460M
YoY Change	-74.13%	-0.08%	1863.16%
Net Earnings / Revenue	-137.86%	-118.63%	-1492.0%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.650M	-$1.316M	-$1.893M
COMMON SHARES
Basic Shares Outstanding	11.71M shares	11.70M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q4	2014 Q3	2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.030M	$10.13M	$2.056M
YoY Change	290.56%	14372.5%	-52.87%
Cash & Equivalents	$8.035M	$9.805M	$1.730M
Short-Term Investments	$0.00	$325.3K	$326.5K
Other Short-Term Assets	$3.220M	$3.810M	$1.620M
YoY Change	98.77%	9425.0%	3950.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$11.61M	$14.20M	$3.681M
YoY Change	215.35%	12923.62%	-29.12%
LONG-TERM ASSETS
Property, Plant & Equipment	$229.5K	$224.5K	$74.19K
YoY Change	209.29%	27019.08%	118.56%
Goodwill			$1.919M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$60.00K	$60.00K	$30.00K
YoY Change	100.0%	1223.04%	-42.24%
Total Long-Term Assets	$2.025M	$2.087M	$1.857M
YoY Change	9.02%	38807.01%	706.24%
TOTAL ASSETS
Total Short-Term Assets	$11.61M	$14.20M	$3.681M
Total Long-Term Assets	$2.025M	$2.087M	$1.857M
Total Assets	$13.63M	$16.28M	$5.538M
YoY Change	146.16%	14137.38%	2.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.130M	$1.910M	$2.050M
YoY Change	3.9%	463.01%	1020.73%
Accrued Expenses		$110.0K
YoY Change		-78.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.300M	$6.192M	$2.053M
YoY Change	206.86%	423.91%	287.95%
LONG-TERM LIABILITIES
Long-Term Debt	$9.160M	$9.160M	$3.960M
YoY Change	131.31%
Other Long-Term Liabilities	$4.430M	$5.410M	$60.00K
YoY Change	7283.33%	982.0%
Total Long-Term Liabilities	$13.58M	$14.56M	$4.020M
YoY Change	237.85%	2812.49%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.300M	$6.192M	$2.053M
Total Long-Term Liabilities	$13.58M	$14.56M	$4.020M
Total Liabilities	$19.88M	$20.75M	$6.073M
YoY Change	227.38%	1133.99%	1047.61%
SHAREHOLDERS EQUITY
Retained Earnings	-$22.32M		-$16.10M
YoY Change	38.62%		-65.53%
Common Stock	$16.07M	$15.92M	$15.56M
YoY Change	3.22%	36472.49%	150268.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$6.249M	-$4.472M	-$534.9K
YoY Change
Total Liabilities & Shareholders Equity	$13.63M	$16.28M	$5.538M
YoY Change	146.16%	14137.38%	2.11%

Cashflow Statement

Concept	2014 Q4	2014 Q3	2013 Q4
OPERATING ACTIVITIES
Net Income	-$1.930M	-$1.544M	-$7.460M
YoY Change	-74.13%	-0.08%	1863.16%
Depreciation, Depletion And Amortization	$10.00K	$10.00K	$30.00K
YoY Change	-66.67%	-200.0%	50.0%
Cash From Operating Activities	-$2.140M	-$2.230M	-$5.780M
YoY Change	-62.98%	-253.79%	5154.55%
INVESTING ACTIVITIES
Capital Expenditures	$40.00K	-$70.00K	-$110.0K
YoY Change	-136.36%	-216.67%	10.0%
Acquisitions
YoY Change
Other Investing Activities	$330.0K	$0.00	$3.890M
YoY Change	-91.52%	-100.0%	-192.4%
Cash From Investing Activities	$370.0K	-$70.00K	$3.780M
YoY Change	-90.21%	-95.0%	-187.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	520.0K	3.550M
YoY Change	-100.0%	-208.33%	-6.82%
NET CHANGE
Cash From Operating Activities	-2.140M	-2.230M	-5.780M
Cash From Investing Activities	370.0K	-70.00K	3.780M
Cash From Financing Activities	0.000	520.0K	3.550M
Net Change In Cash	-1.770M	-1.780M	1.550M
YoY Change	-214.19%	313.95%	-350.0%
FREE CASH FLOW
Cash From Operating Activities	-$2.140M	-$2.230M	-$5.780M
Capital Expenditures	$40.00K	-$70.00K	-$110.0K
Free Cash Flow	-$2.180M	-$2.160M	-$5.670M
YoY Change	-61.55%	-255.4%	56600.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Payments For Royalties PaymentsForRoyalties	20000	EUR
CY2014Q3	us-gaap	Cash Uninsured Amount CashUninsuredAmount	13600000	USD
CY2013Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	187	USD
CY2014Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	105100	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	222763	USD
CY2014Q3	us-gaap	Assets Current AssetsCurrent	14196136	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	3680840	USD
CY2014Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	38850	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9805435	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1729537	USD
CY2014Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	325318	USD
CY2013Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	326494	USD
CY2014Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	3699660	USD
CY2013Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1401859	USD
CY2014Q3	us-gaap	Interest Receivable Current InterestReceivableCurrent	823	USD
CY2013Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	38850	USD
CY2014Q3	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	262451	USD
CY2013Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	115766	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <u><font style="FONT-SIZE: 10pt">Use of Estimates</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.25in"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Management uses its historical records and knowledge of its business in making these estimates. Accordingly, actual results may differ from these estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q3	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	23744	USD
CY2013Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	0	USD
CY2014Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	325045	USD
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	154616	USD
CY2014Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	100499	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	80429	USD
CY2014Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	224546	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	74187	USD
CY2014Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	288474	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	227207	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-980	USD
CY2014Q3	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	20387072	USD
CY2013Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	29945	USD
CY2013Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	16098535	USD
CY2014Q3	us-gaap	Stockholders Equity StockholdersEquity	-4471965	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-534882	USD
CY2014Q3	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	18243	USD
CY2014Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16282719	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5537907	USD
CY2014Q3	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	1500000	USD
CY2013Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	1500000	USD
CY2014Q3	us-gaap	Deposit Assets DepositAssets	55320	USD
CY2013Q4	us-gaap	Deposit Assets DepositAssets	25728	USD
CY2014Q3	us-gaap	Assets Assets	16282719	USD
CY2013Q4	us-gaap	Assets Assets	5537907	USD
CY2014Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1613066	USD
CY2013Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1506509	USD
CY2014Q3	capr	Accounts Payable And Accrued Expenses Related Party Current AccountsPayableAndAccruedExpensesRelatedPartyCurrent	300855	USD
CY2013Q4	capr	Accounts Payable And Accrued Expenses Related Party Current AccountsPayableAndAccruedExpensesRelatedPartyCurrent	382142	USD
CY2014Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	USD
CY2013Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	41855	USD
CY2014Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	111651	USD
CY2013Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	122416	USD
CY2014Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	4166667	USD
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0	USD
CY2014Q3	us-gaap	Liabilities Current LiabilitiesCurrent	6192239	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2052922	USD
CY2014Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	5208332	USD
CY2013Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	0	USD
CY2014Q3	us-gaap	Long Term Loans Payable LongTermLoansPayable	9155857	USD
CY2013Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	3961733	USD
CY2014Q3	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	198256	USD
CY2013Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	58134	USD
CY2014Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	14562445	USD
CY2013Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4019867	USD
CY2014Q3	us-gaap	Liabilities Liabilities	20754684	USD
CY2013Q4	us-gaap	Liabilities Liabilities	6072789	USD
CY2014Q3	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2014Q3	us-gaap	Common Stock Value CommonStockValue	11704	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	11687	USD
CY2014Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	15905010	USD
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	15552946	USD
CY2014Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1607	USD
CY2014Q3	us-gaap	Marketable Securities MarketableSecurities	325318	USD
CY2013Q4	us-gaap	Marketable Securities MarketableSecurities	326494	USD
	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-50
CY2013Q4	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-50
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	1500000	USD
	capr	Number Of Rights Offer For Each Share As Per Merger Agreement NumberOfRightsOfferForEachShareAsPerMergerAgreement	2.07	shares
CY2014Q3	capr	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	10100000	USD
CY2013Q4	capr	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	2100000	USD
	capr	Proceeds From Development Fee ProceedsFromDevelopmentFee	12500000	USD
CY2013	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	1900000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6463932	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5311693	shares
CY2013Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6463932	shares
CY2014Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5311693	shares
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	4600000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	4300000	USD
CY2013Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	1500000	USD
CY2014Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	1500000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	18819	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-627	USD
CY2013Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	30141	USD
CY2014Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-733	USD
CY2014Q3	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	30000	USD
CY2014Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11703774	shares
CY2014Q3	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	6591494	shares
CY2013Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	332281	shares
	capr	Class Of Warrant Or Right Granted ClassOfWarrantOrRightGranted	0	shares
	capr	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	0	shares
CY2014Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	303881	shares
CY2013Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	17.20
	capr	Class Of Warrant Or Right Granted Weighted Average Exercise Price ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice	0
	capr	Class Of Warrant Or Right Exercised Weighted Average Exercise Price ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice	0
CY2014Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	10.02
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.00	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.1200	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P7Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0215	pure
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	177792	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	340693	USD
CY2013Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	71641	USD
CY2014Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	148487	USD
CY2014Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	35722	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	32475	USD
CY2014Q3	us-gaap	Allowance For Notes And Loans Receivable Noncurrent AllowanceForNotesAndLoansReceivableNoncurrent	11757	USD
CY2013Q4	us-gaap	Allowance For Notes And Loans Receivable Noncurrent AllowanceForNotesAndLoansReceivableNoncurrent	6722	USD
CY2014Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2014Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11703774	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11687747	shares
CY2014Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	1800000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P4Y
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11687747	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.26
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.83
CY2014Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	USD
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	69381	USD
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	335910	USD
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	232200	USD
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	96750	USD
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	734241	USD
CY2014Q3	capr	Leases Monthly Payments For First Twelve Months LeasesMonthlyPaymentsForFirstTwelveMonths	16620	USD
CY2014Q3	capr	Leases Monthly Payments For Second Twelve Months LeasesMonthlyPaymentsForSecondTwelveMonths	17285	USD
CY2013Q4	capr	Proceeds From Development Fee ProceedsFromDevelopmentFee	12500000	USD
CY2013Q4	capr	Additional Milestone Payments To Be Received Contingent Upon Exercise Of Options AdditionalMilestonePaymentsToBeReceivedContingentUponExerciseOfOptions	325000000	USD
	us-gaap	Reimbursement Revenue ReimbursementRevenue	1550000	USD
CY2012Q1	us-gaap	Reimbursement Revenue ReimbursementRevenue	195500	USD
	capr	Collaboration Revenue CollaborationRevenue	0	USD
	capr	Collaboration Revenue CollaborationRevenue	3125001	USD
CY2013Q3	capr	Collaboration Revenue CollaborationRevenue	0	USD
CY2014Q3	capr	Collaboration Revenue CollaborationRevenue	1041667	USD
	us-gaap	Revenue From Grants RevenueFromGrants	503233	USD
	us-gaap	Revenue From Grants RevenueFromGrants	259800	USD
CY2013Q3	us-gaap	Revenue From Grants RevenueFromGrants	80432	USD
CY2014Q3	us-gaap	Revenue From Grants RevenueFromGrants	259800	USD
	us-gaap	Revenues Revenues	503233	USD
	us-gaap	Revenues Revenues	3384801	USD
CY2013Q3	us-gaap	Revenues Revenues	80432	USD
CY2014Q3	us-gaap	Revenues Revenues	1301467	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3513548	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5203766	USD
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1010544	USD
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1966889	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1531145	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2332579	USD
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	563948	USD
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	819683	USD
	us-gaap	Operating Expenses OperatingExpenses	5044693	USD
	us-gaap	Operating Expenses OperatingExpenses	7536345	USD
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	1574492	USD
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	2786572	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4541460	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4151544	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1494060	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1485105	USD
	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	-12205	USD
	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	3129	USD
CY2013Q3	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	-27822	USD
CY2014Q3	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	1210	USD
	us-gaap	Interest Expense InterestExpense	33275	USD
	us-gaap	Interest Expense InterestExpense	140122	USD
CY2013Q3	us-gaap	Interest Expense InterestExpense	23353	USD
CY2014Q3	us-gaap	Interest Expense InterestExpense	60091	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-45480	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-136993	USD
CY2013Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-51175	USD
CY2014Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-58881	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4586940	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4288537	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-1545235	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-1543986	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4568121	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4289164	USD
CY2013Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1515094	USD
CY2014Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1544719	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.44
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.37
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.13
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10351294	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	11694004	shares
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10351294	shares
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	11700136	shares
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	347482	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4599	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	20387	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	28352	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	177792	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	347482	USD
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	3067799	USD
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	2297801	USD
	capr	Increase Decrease From Grants Receivable IncreaseDecreaseFromGrantsReceivable	-643368	USD
	capr	Increase Decrease From Grants Receivable IncreaseDecreaseFromGrantsReceivable	259800	USD
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-21788	USD
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	636	USD
	capr	Increase Decrease In Prepaid And Other Current Assets IncreaseDecreaseInPrepaidAndOtherCurrentAssets	-16803	USD
	capr	Increase Decrease In Prepaid And Other Current Assets IncreaseDecreaseInPrepaidAndOtherCurrentAssets	-117663	USD
	us-gaap	Increase Decrease In Deposits Outstanding IncreaseDecreaseInDepositsOutstanding	7640	USD
	us-gaap	Increase Decrease In Deposits Outstanding IncreaseDecreaseInDepositsOutstanding	29592	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	453780	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	106557	USD
	capr	Increase Decrease In Accounts Payable And Accrued Expenses Related Party IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParty	37380	USD
	capr	Increase Decrease In Accounts Payable And Accrued Expenses Related Party IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParty	-81287	USD
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-53567	USD
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-41855	USD
	us-gaap	Increase Decrease In Royalties Payable IncreaseDecreaseInRoyaltiesPayable	-12452	USD
	us-gaap	Increase Decrease In Royalties Payable IncreaseDecreaseInRoyaltiesPayable	-10765	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	33275	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	140122	USD
	us-gaap	Deferred Revenue Revenue Recognized DeferredRevenueRevenueRecognized	0	USD
	us-gaap	Deferred Revenue Revenue Recognized DeferredRevenueRevenueRecognized	9374999	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-6323825	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	3104902	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	226998	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	2818740	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	549	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	52321	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	146685	USD
	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	0	USD
	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	23744	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	36810	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	64514	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	2502611	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-234394	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1812	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	3925066	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	5200791	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4599	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	3926878	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	5205390	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	105664	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	8075898	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	170106	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	275770	USD
	us-gaap	Interest Paid InterestPaid	0	USD
	us-gaap	Interest Paid InterestPaid	0	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2014-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Registrant Name EntityRegistrantName	CAPRICOR THERAPEUTICS, INC.
	dei	Entity Central Index Key EntityCentralIndexKey	0001133869
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Trading Symbol TradingSymbol	CAPR
CY2014Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	11705440	shares
CY2014Q3	us-gaap	Grants Receivable Current GrantsReceivableCurrent	259800	USD
CY2013Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	0	USD
	capr	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	-28400	shares
	capr	Class Of Warrant Or Right Expired Weighted Average Exercise Price ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice	94.00

Files In Submission

Name	View Source	Status
0001144204-14-067974-index-headers.html	Edgar Link	pending
0001144204-14-067974-index.html	Edgar Link	pending
0001144204-14-067974.txt	Edgar Link	pending
0001144204-14-067974-xbrl.zip	Edgar Link	pending
capr-20140930.xml	Edgar Link	completed
capr-20140930.xsd	Edgar Link	pending
capr-20140930_cal.xml	Edgar Link	unprocessable
capr-20140930_def.xml	Edgar Link	unprocessable
capr-20140930_lab.xml	Edgar Link	unprocessable
capr-20140930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v392768_10q.htm	Edgar Link	pending
v392768_ex31-1.htm	Edgar Link	pending
v392768_ex31-2.htm	Edgar Link	pending
v392768_ex32-1.htm	Edgar Link	pending
v392768_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CAPR
CAPRICOR THERAPEUTICS, INC. Stock $capr

2014 Q4 Form 10-Q Financial Statement

#000114420414067974 Filed on November 14, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CAPR CAPRICOR THERAPEUTICS, INC. Stock $capr

2014 Q4 Form 10-Q Financial Statement

#000114420414067974 Filed on November 14, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CAPR
CAPRICOR THERAPEUTICS, INC. Stock $capr